Red Light Therapy for Hyperpigmentation & Dark Spots

Hyperpigmentation — the darkening of skin patches due to excess melanin production — is one of the most common reasons people seek dermatological treatment. Whether it presents as post-inflammatory hyperpigmentation (PIH) after acne, melasma across the cheeks and forehead, sun-induced age spots, or uneven skin tone, the underlying mechanism involves melanocytes producing and distributing more melanin than surrounding skin.

Red light therapy is frequently marketed for hyperpigmentation, but the reality is considerably more nuanced than the marketing suggests. Some forms of hyperpigmentation may respond to specific wavelengths, others are unlikely to improve, and in certain cases, the wrong wavelength choice could theoretically make things worse. This article separates the evidence from the claims.

Understanding Melanocyte Biology

To evaluate whether red light therapy can help hyperpigmentation, you need to understand how melanin is produced and why it sometimes goes wrong.

How Melanin Is Made

Melanocytes sit in the basal layer of the epidermis and produce melanin through a process called melanogenesis. The key steps:

Tyrosinase activation — the enzyme tyrosinase catalyses the conversion of the amino acid tyrosine to DOPA and then to dopaquinone, the first committed step in melanin synthesis
Melanosome formation — melanin is packaged into membrane-bound organelles called melanosomes within the melanocyte
Melanosome transfer — mature melanosomes are transferred from melanocyte dendrites to surrounding keratinocytes via a process called cytocrine secretion
Keratinocyte distribution — keratinocytes distribute melanosomes as a UV-protective cap over their nuclei

Hyperpigmentation can result from abnormalities at any of these stages: increased tyrosinase activity, more melanosomes being produced, more efficient transfer to keratinocytes, or slower clearance of melanin-laden keratinocytes from the epidermis.

Types of Hyperpigmentation

Different types of hyperpigmentation have distinct causes, which affects whether red light therapy is likely to help:

Post-inflammatory hyperpigmentation (PIH) — occurs after skin injury, inflammation, or conditions like acne. The inflammatory process stimulates melanocytes to overproduce melanin. PIH is more common and more severe in darker skin tones (Fitzpatrick types III–VI). It is typically epidermal (superficial) and resolves over months to years as melanin-laden keratinocytes turn over.

Melasma — a chronic, hormonally driven condition causing symmetrical brown or grey-brown patches, typically on the face. It involves both increased melanocyte activity and increased vascularity in affected areas. Melasma has epidermal, dermal, and mixed subtypes. The dermal component is particularly resistant to treatment because melanin deposited in the dermis is not cleared by normal epidermal turnover.

Solar lentigines (age spots/sun spots) — caused by chronic UV exposure, these involve localised increases in melanocyte number and activity. They are typically well-defined, flat, brown lesions on sun-exposed areas.

Post-inflammatory erythema (PIE) — often confused with PIH, PIE involves redness rather than brown discoloration. It results from damaged capillaries and inflammation rather than melanin overproduction. This is a separate condition that responds differently to treatment.

What the Evidence Shows

Red Light (630–660 nm) and Melanocytes

The interaction between red light and melanocytes is complex and not entirely resolved in the literature.

In vitro studies (cell culture) have produced conflicting results:

Some studies report that 630–660 nm red light reduces melanogenesis by inhibiting tyrosinase activity and reducing melanosome transfer. Kim et al. (2012) demonstrated that 630 nm LED irradiation (3 J/cm²) decreased melanin content in human melanocyte cultures by approximately 25% compared with controls.
Other studies suggest that red light can stimulate melanocyte proliferation and melanin production, particularly at higher doses. Lan et al. (2009) found that 633 nm light at 0.5–1.5 J/cm² increased melanin synthesis in primary human melanocytes, while higher doses (6 J/cm²) suppressed it — a classic biphasic dose response.

This dose-dependency is critical. It suggests that the relationship between red light and pigmentation is not simply “red light reduces dark spots” — the outcome depends on the specific dose, and getting it wrong could theoretically worsen hyperpigmentation.

Clinical Studies for Hyperpigmentation

Lee et al. (2013) published a split-face study in Lasers in Surgery and Medicine examining 830 nm NIR LED treatment for melasma. Twenty female patients received LED treatment (830 nm, 60 J/cm²) to one side of the face twice weekly for 8 weeks. The treated side showed significant reduction in MASI (Melasma Area and Severity Index) scores compared with the untreated side (p < 0.01). Melanin index measurements confirmed reduced pigmentation on the treated side.

Khoury et al. (2020) conducted a randomised controlled trial examining 633 nm LED for post-inflammatory hyperpigmentation in acne patients. After 12 sessions (twice weekly for 6 weeks), the LED group showed modest but statistically significant improvement in PIH compared with sham, though the effect was less pronounced than with topical treatments (hydroquinone or azelaic acid).

Na et al. (2017) examined combination 660 nm red and 850 nm NIR LED therapy for skin rejuvenation, with pigmentation as a secondary outcome. While the primary focus was on wrinkles and collagen, melanin index measurements showed modest improvements in overall skin tone evenness in the treatment group.

The Melasma Problem

Melasma deserves special attention because it is both common and notoriously difficult to treat.

The evidence for red/NIR light therapy in melasma is mixed:

Potential benefits:

Anti-inflammatory effects may reduce the vascular component of melasma (which contributes to its appearance)
Modulation of melanocyte activity at appropriate doses
The Lee et al. (2013) study with 830 nm showed measurable improvement

Potential risks:

Heat generation from any light source can trigger melanocyte activation — heat-induced pigmentation (thermal stimulation of melanogenesis) is a recognised phenomenon
Some wavelengths may stimulate melanocyte proliferation if the dose is not carefully controlled
Melasma is exacerbated by visible light (particularly blue and violet light, 400–500 nm), and some red light therapy devices emit small amounts of shorter wavelengths

The consensus: Red light therapy is not a first-line treatment for melasma. Topical treatments (hydroquinone, tretinoin, azelaic acid, tranexamic acid), sun protection, and professional procedures (chemical peels, laser toning) have substantially stronger evidence. Red light may serve as a cautious adjunct, but careful attention to wavelength purity and dose is essential.

Wavelength Caution: What Could Make Things Worse

This is a critical section that many red light therapy sources omit.

Blue and violet light (400–500 nm) — these wavelengths directly stimulate opsin-3 receptors on melanocytes, triggering melanogenesis. Some studies suggest that visible light contributes to melasma persistence, particularly in darker skin tones. If your “red light therapy” device emits any significant blue or violet light (which is unlikely with quality devices but possible with cheap, poorly-filtered products), it could worsen pigmentation.

Green light (500–570 nm) — limited data, but some evidence suggests it can modulate melanocyte activity in both directions depending on dose and skin type.

Intense pulsed light (IPL) — sometimes confused with LED-based red light therapy, IPL uses broad-spectrum light including wavelengths that are strongly absorbed by melanin. IPL is used therapeutically for solar lentigines but can worsen melasma and PIH, particularly in darker skin tones. IPL is not red light therapy and should not be conflated with it.

High-power red/NIR — excessive energy delivery (above 10–12 J/cm²) generates heat in the skin, and thermal stimulation of melanocytes is a documented trigger for pigmentation. This is particularly relevant for people with melasma.

Skin Tone Considerations

The interaction between light therapy and pigmentation is influenced by baseline skin tone, and this is an area where generalised advice can be harmful.

Fitzpatrick Types I–III (Fair to Light Skin)

PIH is less common and typically resolves faster
Lower melanin content means less light absorption in the epidermis, allowing more photons to reach target chromophores (mitochondria)
Lower risk of paradoxical hyperpigmentation from red/NIR therapy
Red light therapy at standard protocols is generally well-tolerated

Fitzpatrick Types IV–VI (Medium to Dark Skin)

PIH is more common, more severe, and slower to resolve
Higher epidermal melanin absorbs more light energy, which has two consequences: (1) less light reaches deeper targets, potentially reducing efficacy; (2) more energy is converted to heat in the epidermis, increasing risk of thermal stimulation of melanocytes
Start with lower energy densities (2–3 J/cm² rather than 4–6 J/cm²) and monitor for any darkening of treated areas
Melasma in darker skin tones is particularly susceptible to worsening from any form of energy-based treatment
Consider using NIR wavelengths (830–850 nm) rather than red (630–660 nm), as NIR is absorbed less by melanin and penetrates more evenly regardless of skin tone

For a more detailed discussion, see our page on red light therapy and dark skin.

Protocol for Hyperpigmentation

Given the complexity of the evidence, protocols must be tailored to the type of hyperpigmentation and skin tone.

For Post-Inflammatory Hyperpigmentation (PIH)

PIH is the most promising indication because the inflammatory component is well-suited to PBM’s anti-inflammatory mechanism, and accelerating epidermal turnover can help clear melanin-laden keratinocytes.

Wavelength: 630–660 nm (red) and/or 830 nm (NIR)
Energy density: 3–6 J/cm² per session (start at the lower end for darker skin tones)
Frequency: 3–5 sessions per week
Duration: Minimum 6–8 weeks to assess response
Combine with: Topical niacinamide (5%), vitamin C serum, or azelaic acid for synergistic effects. Continue diligent sun protection (SPF 30+ daily)

For Melasma

Approach with caution. Red light therapy should not be the primary treatment.

Wavelength: 830 nm (NIR) preferred over 630–660 nm (red) — less melanin absorption, lower risk of thermal stimulation
Energy density: 2–4 J/cm² per session (err on the conservative side)
Frequency: 2–3 sessions per week initially
Duration: 8–12 weeks minimum
Essential precaution: Monitor treated areas closely for any darkening. Discontinue if pigmentation worsens
Combine with: Topical tranexamic acid, azelaic acid, or prescription tretinoin/hydroquinone. Sun protection is non-negotiable — even moderate UV exposure can reverse any improvement

For Solar Lentigines (Age Spots)

Red light therapy alone is unlikely to produce dramatic improvement for established solar lentigines. The melanocyte changes in solar lentigines are structural (increased melanocyte number) rather than purely functional (increased melanin output), and PBM does not reduce melanocyte number.

Realistic expectation: Mild improvement in overall skin tone; minimal impact on well-defined individual age spots
More effective options: Cryotherapy, IPL (for fair skin), Q-switched laser, or topical retinoids
Role of red light: Supporting overall skin quality, collagen production, and post-procedure healing rather than directly treating the lentigines themselves

For Post-Inflammatory Erythema (PIE)

If your concern is redness rather than brown pigmentation, red light therapy is more clearly beneficial. PBM reduces inflammation, supports vascular repair, and accelerates skin healing.

Wavelength: 630–660 nm (red) — targets superficial inflammation and capillary repair
Energy density: 3–6 J/cm²
Frequency: 3–5 sessions per week
Duration: 4–8 weeks

Combining Red Light Therapy with Other Treatments

Red light therapy is most likely to benefit hyperpigmentation as part of a comprehensive approach rather than as a standalone treatment.

Effective Combinations

Red Light Therapy +	Mechanism	Evidence
Topical vitamin C (L-ascorbic acid)	Tyrosinase inhibition + antioxidant	Moderate
Topical niacinamide (5%)	Reduces melanosome transfer	Strong for niacinamide alone
Azelaic acid (15–20%)	Tyrosinase inhibition + anti-inflammatory	Strong
Tranexamic acid (topical or oral)	Plasminogen inhibition, reduces melanogenesis	Strong for melasma
Tretinoin (0.025–0.05%)	Accelerates epidermal turnover	Strong (prescription)
SPF 30–50 daily	Prevents UV-driven melanogenesis	Essential for all types

Timing

Apply topical actives after red light therapy sessions, not before (some actives, particularly retinoids, may increase photosensitivity — see the medications interaction guide)
Allow 15–30 minutes after PBM before applying products to clean, dry skin

Comparison: Red Light Therapy vs Other Hyperpigmentation Treatments

Treatment	Efficacy for PIH	Efficacy for Melasma	Efficacy for Age Spots	Risk of Worsening	Cost
Hydroquinone (2–4%)	High	High	Moderate	Low (with proper use)	£10–30
Tretinoin	Moderate-High	Moderate	Moderate	Low	£15–50 (prescription)
Chemical peels	High	Moderate-High	Moderate	Moderate (dark skin)	£80–200/session
Q-switched laser	Low	Low (often worsens)	High	High (melasma)	£150–500/session
IPL	Moderate	Low (often worsens)	High (fair skin)	High (dark skin)	£100–300/session
Red light therapy	Low-Moderate	Low (uncertain)	Low	Low	£100–600 (device)
Topical vitamin C	Moderate	Low-Moderate	Low	Very low	£15–40

The Honest Assessment

Red light therapy for hyperpigmentation sits in a complicated position. The biological mechanisms are plausible — anti-inflammatory effects can reduce the drivers of PIH, and modulation of melanocyte activity has been demonstrated in cell culture. But the clinical evidence is limited, and the dose-response relationship is not fully characterised.

Where red light therapy may genuinely help:

Post-inflammatory hyperpigmentation (PIH), particularly recent-onset PIH with an ongoing inflammatory component
Post-inflammatory erythema (redness)
Supporting overall skin health and collagen remodelling alongside topical treatments
Post-procedure healing (after chemical peels or laser treatments)

Where red light therapy is unlikely to help significantly:

Established solar lentigines (age spots)
Long-standing dermal melasma
Genetic or constitutional pigmentation differences

Where caution is warranted:

Active melasma — monitor closely for worsening
Darker skin tones — start with lower doses and NIR wavelengths
Any device that emits wavelengths outside the red/NIR range

If you have hyperpigmentation, the evidence-based first steps remain topical treatments (vitamin C, niacinamide, azelaic acid, or prescription agents) combined with rigorous sun protection. Red light therapy can be a reasonable complementary approach, but setting realistic expectations is essential: expect gradual, modest improvement rather than dramatic clearing.

This article is for informational purposes only and does not constitute medical advice. If you have concerns about hyperpigmentation or changes in skin pigmentation, consult a dermatologist for proper assessment and treatment. Red light therapy should complement — not replace — established topical and medical treatments.